Virax Biolabs Group Limited (VRAX) Total Return Calculator with Dividends Reinvested

Virax Biolabs Group Limited

Popular:

The total return for Virax Biolabs Group Limited (VRAX) stock is -84.63% over the past 12 months. So far it's down 45.57% this year. The 5-year total return is -99.89%, meaning $10,000 invested in VRAX stock 5 years ago would be worth $11 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in VRAX 1 year ago, it would be worth $1,537 today — you'd have lost $8,463.

With Dividends Reinvested$1,537-84.63%

Price Only (No DRIP)$1,537-84.63%

Period2025-03-05 → 2026-03-04

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in VRAX

1Y$1,537-$8,463 (-84.6%)-84.6% CAGR

3Y$315-$9,685 (-96.8%)-68.4% CAGR

5Y$11-$9,989 (-99.9%)-74.2% CAGR

10Y$11-$9,989 (-99.9%)-49.2% CAGR

15Y$11-$9,989 (-99.9%)-36.3% CAGR

20Y$11-$9,989 (-99.9%)-28.7% CAGR

30Y$11-$9,989 (-99.9%)-20.2% CAGR

Virax Biolabs Group Limited did not pay dividends during this period. Total return = price return.

Loading VRAX total return...

As of 2026-03-05

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-45.57%	—	-45.57%	—	$5,443
1Y	-84.63%	-84.63%	-84.63%	—	$1,537
3Y	-96.85%	-68.41%	-96.85%	—	$315
5Y	-99.89%	-74.18%	-99.89%	—	$11
10Y	-99.89%	-49.18%	-99.89%	—	$11
15Y	-99.89%	-36.32%	-99.89%	—	$11
20Y	-99.89%	-28.72%	-99.89%	—	$11
30Y	-99.89%	-20.20%	-99.89%	—	$11

Risk & Highlights

Best Year+64.23%2024

Worst Year-95.99%2022

Max Drawdown-88.00%2025-03-11 → 2026-02-17

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-40.70%	-40.70%	—	+0.41%	-41.1pp
2025	-84.34%	-84.34%	—	+16.64%	-101.0pp
2024	+64.23%	+64.23%	—	+24.00%	+40.2pp
2023	-81.82%	-81.82%	—	+24.81%	-106.6pp
2022	-95.99%	-95.99%	—	-19.95%	-76.0pp

VRAX underperformed the S&P 500 by 101.32pp over the past year (-84.63% vs +16.68%).

Loading summary...

VRAX Peers' Total Return

Biotechnology · Top 11 by market cap

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
VRAXVirax Biolabs Group Limited	$2M	-5.9%	-45.6%	-84.6%	—	-96.8%	-99.9%	-99.9%
VRTXVertex Pharmaceuticals Incorporated	$121.4B	+4.2%	+5.7%	-2.8%	—	+63.9%	+125.4%	+425.4%
REGNRegeneron Pharmaceuticals, Inc.	$108.4B	+2.7%	+1.6%	+15.1%	+0.5pp	+1.5%	+71.6%	+94.0%
PHGEBiomX Inc.	$82.8B	+38.2%	+194.4%	-48.8%	—	-93.2%	-99.5%	-99.7%
ARGXargenx SE	$46.4B	-8.6%	-10.8%	+17.8%	—	+119.3%	+158.7%	+3159.0%
ALNYAlnylam Pharmaceuticals, Inc.	$43.3B	-1.2%	-18.2%	+31.3%	—	+63.9%	+128.3%	+444.7%
CAICaris Life Sciences, Inc.	$33.2B	-6.5%	-26.4%	-29.1%	—	-29.1%	-29.1%	-29.1%
RPRXRoyalty Pharma plc	$26.8B	+7.6%	+22.7%	+43.1%	+2.7pp	+42.2%	+21.0%	+16.7%
BNTXBioNTech SE	$26.0B	-1.6%	+7.4%	-9.6%	—	-21.1%	+10.1%	+643.8%
MRNAModerna, Inc.	$22.6B	+41.4%	+87.3%	+64.2%	—	-59.9%	-56.3%	+210.8%
ROIVRoivant Sciences Ltd.	$21.4B	+39.6%	+34.6%	+175.9%	—	+275.1%	+197.6%	+183.8%

Compare:VRAX vs VRTX VRAX vs REGN VRAX vs PHGE VRAX vs VRTX vs REGN

About VRAX Dividend Returns

Virax Biolabs Group Limited (VRAX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of VRAX over the past year?

Virax Biolabs Group Limited (VRAX) delivered a return of -84.63% over the past year. Since VRAX does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in VRAX be worth today?

A $10,000 investment in Virax Biolabs Group Limited one year ago would be worth $1,537 today, representing a loss of $8,463.

Q3Does VRAX pay dividends?

Virax Biolabs Group Limited (VRAX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For VRAX, the total return equals the price-only return.

Q4Did VRAX beat the S&P 500?

No, Virax Biolabs Group Limited (VRAX) underperformed the S&P 500 by 101.32 percentage points over the past year. VRAX delivered a total return of -84.63%, compared to the S&P 500's 16.68%. This means a passive S&P 500 index fund outperformed VRAX by 101.32pp during this period.

Q5What is VRAX's worst drawdown?

Virax Biolabs Group Limited (VRAX) experienced a maximum drawdown of -88.00% over the past year, declining from its peak on 2025-03-11 to its trough on 2026-02-17. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is VRAX's long-term total return over 10, 20, or 30 years?

Virax Biolabs Group Limited (VRAX) has delivered strong long-term returns with dividends reinvested. Over 10 years, the total return is -99.9% (-49.2% CAGR) — $10,000 would have grown to $11. Over 20 years: -99.9% total return (-28.7% CAGR) — $10,000 → $11. Over 30 years: -99.9% total return (-20.2% CAGR) — $10,000 → $11. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was VRAX's best and worst year?

Virax Biolabs Group Limited's best calendar year was 2024 with a total return of 64.2%. Its worst year was 2022 with a total return of -96.0%. This range shows the volatility investors should expect — the difference between the best and worst year is 160.2 percentage points.